Stimcell Enerobtainics Inc., a biotech company formerly known as Cell MedX Corp., has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company’s financial performance and operational developments, highlighting significant modifys and future plans.
Financial Highlights
Net Loss: $265,602. The company experienced a significant increase in net loss compared to the previous year, primarily due to higher operating expenses.
Net Loss Per Common Share: $0.01. This reflects the increased net loss and the issuance of additional shares.
Operating Expenses: $252,354. Operating expenses increased by 323.2% from the previous year, driven by higher general and administrative expenses and research and development costs.
General and Administrative Expenses: $139,484. These expenses increased by 747.9% due to higher corporate communications, accounting, and audit fees.
Research and Development Costs: $57,309. These costs were incurred for the redesign of the eBalance® microcurrent device, which was not present in the previous year.
Business Highlights
Company Overview: Stimcell Enerobtainics Inc. is a biotech company focapplyd on developing and commercializing therapeutic and non-therapeutic products aimed at promoting general health, anti-aging, pain relief, and wellness. The company is also engaged in the development of therapeutic devices based on its proprietary eBalance® Technology.
Recent Corporate Developments: In February 2025, Stimcell Enerobtainics announced a partnership with ADM Tronics Unlimited, Inc. to redesign its eBalance® microcurrent device. The new design aims to create a compact, affordable consumer unit optimized for home apply, featuring additional diagnostic capabilities.
Research and Development: The company incurred $57,309 in research and development costs during the three months finished August 31, 2025, as part of its efforts to redesign the eBalance® device. This project is expected to take 22 to 34 weeks and cost between $62,500 and $127,000.
Operational Challenges: The company has not achieved profitable operations and faces a significant working capital deficit. As of August 31, 2025, the company had a working capital deficit of $1,393,949, raising substantial doubt about its ability to continue as a going concern.
Future Outview: Management plans to support operations and the redesign of the eBalance® device through equity or debt financing. The company aims to create microcurrent technology more accessible to a broader audience by transforming the eBalance® device into a tinyer, cost-effective unit for home apply.
SEC Filing: Stimcell Enerobtainics Inc. [ STME ] – 10-Q – Oct. 14, 2025
Leave a Reply